Characterization of drug-drug salt forms of metformin and aspirin with improved physicochemical properties

A drug-drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization mechanism was supposed for the transition from anhydrate to hemihydrate. The modulated solubility properties of the dual drug would help to ove...

Full description

Saved in:
Bibliographic Details
Published inCrystEngComm Vol. 21; no. 25; pp. 377 - 3773
Main Authors Zhou, Wen-Xiu, Zhao, Hong-Wei, Chen, Huan-Huan, Zhang, Zai-Yong, Chen, Dong-Ying
Format Journal Article
LanguageEnglish
Published Cambridge Royal Society of Chemistry 2019
Subjects
Aspirin
Crystallography
Metformin
Recrystallization
Side effects
Online AccessGet full text

Cover

Abstract A drug-drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization mechanism was supposed for the transition from anhydrate to hemihydrate. The modulated solubility properties of the dual drug would help to overcome the associated gastrointestinal side effects to some extent. A salt between two old drugs was synthesized and two phases were discovered with improved physicochemical properties.
AbstractList A drug–drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization mechanism was supposed for the transition from anhydrate to hemihydrate. The modulated solubility properties of the dual drug would help to overcome the associated gastrointestinal side effects to some extent.
A drug-drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization mechanism was supposed for the transition from anhydrate to hemihydrate. The modulated solubility properties of the dual drug would help to overcome the associated gastrointestinal side effects to some extent. A salt between two old drugs was synthesized and two phases were discovered with improved physicochemical properties.
Author Chen, Huan-Huan
Zhang, Zai-Yong
Zhou, Wen-Xiu
Zhao, Hong-Wei
Chen, Dong-Ying
AuthorAffiliation Chinese Academy of Sciences
Research Center for Pharmaceutical Quality Control and Solid-State Chemistry
Shanghai Institute of Materia Medica
University of Chinese Academy of Sciences
AuthorAffiliation_xml – name: Shanghai Institute of Materia Medica
– name: Research Center for Pharmaceutical Quality Control and Solid-State Chemistry
– name: University of Chinese Academy of Sciences
– name: Chinese Academy of Sciences
Author_xml – sequence: 1
  givenname: Wen-Xiu
  surname: Zhou
  fullname: Zhou, Wen-Xiu
– sequence: 2
  givenname: Hong-Wei
  surname: Zhao
  fullname: Zhao, Hong-Wei
– sequence: 3
  givenname: Huan-Huan
  surname: Chen
  fullname: Chen, Huan-Huan
– sequence: 4
  givenname: Zai-Yong
  surname: Zhang
  fullname: Zhang, Zai-Yong
– sequence: 5
  givenname: Dong-Ying
  surname: Chen
  fullname: Chen, Dong-Ying
BookMark eNpNkE1LxDAQhoOs4O7qxbsQ8CZU89Gm7VHK-oELXvRcssnUZt02Nckq6683dUW9zLy8PMzAM0OT3vaA0Ckll5Tw8kqVCgjhef56gKY0FSIpCOeTf_kIzbxfE0JTSskUratWOqkCOPMpg7E9tg3WbvuSjAN7uQm4sa7zY99BGLPpsew1ln4wLuYPE1psusHZd9B4aHfeKKta6IySGxzrAVww4I_RYSM3Hk5-9hw93yyeqrtk-Xh7X10vE8VpERKuWMm4FFpokKKUQmopGVuVAjRVlK9yRlRegAaVgm5WKc9VVuSZFg1jpAE-R-f7u_H12xZ8qNd26_r4smYszUTUw7JIXewp5az3Dpp6cKaTbldTUo8u66qsFt8uHyJ8toedV7_cn2v-BS-ldW0
CitedBy_id crossref_primary_10_1021_acsomega_3c06721
crossref_primary_10_1371_journal_pone_0287267
crossref_primary_10_1016_j_ijpharm_2024_123857
crossref_primary_10_1039_D2NJ00453D
crossref_primary_10_3390_pharmaceutics16030382
crossref_primary_10_1039_C9CE01504C
crossref_primary_10_1016_j_ijpharm_2023_123555
crossref_primary_10_1016_j_ijpharm_2022_121541
crossref_primary_10_3390_pharmaceutics15020449
crossref_primary_10_1021_acs_cgd_4c00562
crossref_primary_10_1016_j_molliq_2021_116894
crossref_primary_10_1016_j_ejpb_2020_05_031
crossref_primary_10_1021_acs_cgd_1c00229
crossref_primary_10_1039_D3CE01000G
crossref_primary_10_3390_molecules26144377
Cites_doi 10.1002/jps.20894
10.1016/j.addr.2017.07.001
10.1039/C5CC08216A
10.1111/dme.13040
10.1002/jps.2600610419
10.1021/acs.cgd.8b00718
10.1097/PPO.0000000000000103
10.1016/j.cca.2013.11.028
10.1021/acs.cgd.6b00639
10.1042/BJ20150125
10.1039/C5CC10297A
10.1146/annurev-med-062613-093128
10.1007/s00535-009-0068-0
10.1056/NEJM196005262622102
10.1016/j.jddst.2015.09.019
10.1016/j.scitotenv.2018.02.306
10.1016/j.ygyno.2017.10.026
10.1016/j.yrtph.2017.12.023
10.1107/S2052520618013185
10.3121/cmr.2013.1197
10.1016/j.drudis.2016.02.001
10.1056/NEJMoa1804988
10.1002/jps.22258
10.1039/c3ce26986h
10.1021/cg400518w
10.1039/B904616J
ContentType Journal Article
Copyright Copyright Royal Society of Chemistry 2019
Copyright_xml – notice: Copyright Royal Society of Chemistry 2019
DBID AAYXX
CITATION
7U5
8FD
L7M
DOI 10.1039/c9ce00377k
DatabaseName CrossRef
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
DatabaseTitle CrossRef
Technology Research Database
Advanced Technologies Database with Aerospace
Solid State and Superconductivity Abstracts
DatabaseTitleList Technology Research Database

CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1466-8033
EndPage 3773
ExternalDocumentID 10_1039_C9CE00377K
c9ce00377k
GroupedDBID 0-7
0R
1TJ
29F
5GY
70
705
70J
7~J
AAEMU
AAGNR
AAIWI
AANOJ
AAPBV
ABDVN
ABGFH
ABPTK
ABRYZ
ACGFS
ACLDK
ADACO
ADMRA
ADSRN
AENEX
AFVBQ
AGKEF
AGSTE
AGSWI
ALMA_UNASSIGNED_HOLDINGS
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CKLOX
CS3
E3Z
EBS
ECGLT
EE0
EF-
EJD
GNO
HZ
H~N
IDZ
IPNFZ
J3I
JG
KC5
N9A
O9-
OK1
P2P
R7B
RCNCU
RIG
RNS
RPMJG
RRA
RRC
RSCEA
SKA
SLH
VH6
-JG
0R~
6J9
70~
AAJAE
AAMEH
AAWGC
AAXHV
AAXPP
AAYXX
ABASK
ABEMK
ABJNI
ABPDG
ABXOH
ACGFO
AEFDR
AENGV
AESAV
AETIL
AFLYV
AFOGI
AGEGJ
AGRSR
AHGCF
ANUXI
APEMP
CITATION
GGIMP
H13
HZ~
RAOCF
7U5
8FD
L7M
ID FETCH-LOGICAL-c318t-3c2923a6d6dea69a6adaa22b96ed1c13b720c78edec4edfb437c5875d6f220fe3
ISSN 1466-8033
IngestDate Thu Oct 10 16:20:39 EDT 2024
Fri Aug 23 02:41:52 EDT 2024
Sat Jan 08 03:36:49 EST 2022
IsPeerReviewed true
IsScholarly true
Issue 25
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c318t-3c2923a6d6dea69a6adaa22b96ed1c13b720c78edec4edfb437c5875d6f220fe3
Notes For ESI and crystallographic data in CIF or other electronic format see DOI
10.1039/c9ce00377k
Electronic supplementary information (ESI) available: Experimental procedure, characterization data and crystallographic details. CCDC
1860886
and
1860888
ORCID 0000-0002-4928-9760
PQID 2245603725
PQPubID 2047491
PageCount 4
ParticipantIDs proquest_journals_2245603725
crossref_primary_10_1039_C9CE00377K
rsc_primary_c9ce00377k
PublicationCentury 2000
PublicationDate 2019-00-00
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – year: 2019
  text: 2019-00-00
PublicationDecade 2010
PublicationPlace Cambridge
PublicationPlace_xml – name: Cambridge
PublicationTitle CrystEngComm
PublicationYear 2019
Publisher Royal Society of Chemistry
Publisher_xml – name: Royal Society of Chemistry
References Gonçalves (C9CE00377K-(cit16)/*[position()=1]) 2014; 429
Chen (C9CE00377K-(cit26)/*[position()=1]) 2010; 99
Thipparaboina (C9CE00377K-(cit1)/*[position()=1]) 2016; 21
Adak (C9CE00377K-(cit8)/*[position()=1]) 2018; 92
Ford (C9CE00377K-(cit17)/*[position()=1]) 2015; 468
Nanubolu (C9CE00377K-(cit13)/*[position()=1]) 2013; 15
Levy (C9CE00377K-(cit19)/*[position()=1]) 1960; 262
Bowman (C9CE00377K-(cit21)/*[position()=1]) 2018; 379
Morales (C9CE00377K-(cit9)/*[position()=1]) 2015; 66
Takiuchi (C9CE00377K-(cit14)/*[position()=1]) 2018; 148
Búdová (C9CE00377K-(cit18)/*[position()=1]) 2018; 18
Putra (C9CE00377K-(cit5)/*[position()=1]) 2016; 16
Dujic (C9CE00377K-(cit11)/*[position()=1]) 2016; 33
Kim (C9CE00377K-(cit12)/*[position()=1]) 2015; 30
Duggirala (C9CE00377K-(cit7)/*[position()=1]) 2016; 52
Mirza (C9CE00377K-(cit27)/*[position()=1]) 2007; 96
Ittaman (C9CE00377K-(cit15)/*[position()=1]) 2014; 12
Peng (C9CE00377K-(cit3)/*[position()=1]) 2018; 74
Shiotani (C9CE00377K-(cit20)/*[position()=1]) 2009; 44
Tsuchiya (C9CE00377K-(cit23)/*[position()=1]) 1972; 61
Vioglio (C9CE00377K-(cit2)/*[position()=1]) 2017; 117
He (C9CE00377K-(cit10)/*[position()=1]) 2015; 21
Briones (C9CE00377K-(cit22)/*[position()=1]) 2018; 630
Wang (C9CE00377K-(cit6)/*[position()=1]) 2016; 52
Aitipamula (C9CE00377K-(cit4)/*[position()=1]) 2009; 11
Geng (C9CE00377K-(cit25)/*[position()=1]) 2013; 13
References_xml – issn: 1976
  publication-title: U.S. Pat.
  doi: Bohuon
– volume: 96
  start-page: 2399
  year: 2007
  ident: C9CE00377K-(cit27)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.20894
  contributor:
    fullname: Mirza
– volume: 117
  start-page: 86
  year: 2017
  ident: C9CE00377K-(cit2)/*[position()=1]
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/j.addr.2017.07.001
  contributor:
    fullname: Vioglio
– volume: 52
  start-page: 640
  year: 2016
  ident: C9CE00377K-(cit7)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C5CC08216A
  contributor:
    fullname: Duggirala
– volume: 33
  start-page: 511
  year: 2016
  ident: C9CE00377K-(cit11)/*[position()=1]
  publication-title: Diabetic Med.
  doi: 10.1111/dme.13040
  contributor:
    fullname: Dujic
– volume: 61
  start-page: 586
  year: 1972
  ident: C9CE00377K-(cit23)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600610419
  contributor:
    fullname: Tsuchiya
– volume: 18
  start-page: 5287
  year: 2018
  ident: C9CE00377K-(cit18)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.8b00718
  contributor:
    fullname: Búdová
– volume: 21
  start-page: 70
  year: 2015
  ident: C9CE00377K-(cit10)/*[position()=1]
  publication-title: Cancer J.
  doi: 10.1097/PPO.0000000000000103
  contributor:
    fullname: He
– volume: 429
  start-page: 76
  year: 2014
  ident: C9CE00377K-(cit16)/*[position()=1]
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2013.11.028
  contributor:
    fullname: Gonçalves
– volume: 16
  start-page: 3577
  year: 2016
  ident: C9CE00377K-(cit5)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.6b00639
  contributor:
    fullname: Putra
– volume: 468
  start-page: 125
  year: 2015
  ident: C9CE00377K-(cit17)/*[position()=1]
  publication-title: Biochem. J.
  doi: 10.1042/BJ20150125
  contributor:
    fullname: Ford
– volume: 52
  start-page: 3572
  year: 2016
  ident: C9CE00377K-(cit6)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C5CC10297A
  contributor:
    fullname: Wang
– volume: 66
  start-page: 17
  year: 2015
  ident: C9CE00377K-(cit9)/*[position()=1]
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev-med-062613-093128
  contributor:
    fullname: Morales
– volume: 44
  start-page: 717
  year: 2009
  ident: C9CE00377K-(cit20)/*[position()=1]
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-009-0068-0
  contributor:
    fullname: Shiotani
– volume: 262
  start-page: 1053
  year: 1960
  ident: C9CE00377K-(cit19)/*[position()=1]
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM196005262622102
  contributor:
    fullname: Levy
– volume: 30
  start-page: 90
  year: 2015
  ident: C9CE00377K-(cit12)/*[position()=1]
  publication-title: J. Drug Delivery Sci. Technol.
  doi: 10.1016/j.jddst.2015.09.019
  contributor:
    fullname: Kim
– volume: 630
  start-page: 1258
  year: 2018
  ident: C9CE00377K-(cit22)/*[position()=1]
  publication-title: Sci. Total Environ.
  doi: 10.1016/j.scitotenv.2018.02.306
  contributor:
    fullname: Briones
– volume: 148
  start-page: 222
  year: 2018
  ident: C9CE00377K-(cit14)/*[position()=1]
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2017.10.026
  contributor:
    fullname: Takiuchi
– volume: 92
  start-page: 324
  year: 2018
  ident: C9CE00377K-(cit8)/*[position()=1]
  publication-title: Regul. Toxicol. Pharmacol.
  doi: 10.1016/j.yrtph.2017.12.023
  contributor:
    fullname: Adak
– volume: 74
  start-page: 738
  year: 2018
  ident: C9CE00377K-(cit3)/*[position()=1]
  publication-title: Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.
  doi: 10.1107/S2052520618013185
  contributor:
    fullname: Peng
– volume: 12
  start-page: 147
  year: 2014
  ident: C9CE00377K-(cit15)/*[position()=1]
  publication-title: Clin. Med. Res.
  doi: 10.3121/cmr.2013.1197
  contributor:
    fullname: Ittaman
– volume: 21
  start-page: 481
  year: 2016
  ident: C9CE00377K-(cit1)/*[position()=1]
  publication-title: Drug Discovery Today
  doi: 10.1016/j.drudis.2016.02.001
  contributor:
    fullname: Thipparaboina
– volume: 379
  start-page: 1529
  year: 2018
  ident: C9CE00377K-(cit21)/*[position()=1]
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1804988
  contributor:
    fullname: Bowman
– volume: 99
  start-page: 4032
  year: 2010
  ident: C9CE00377K-(cit26)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.22258
  contributor:
    fullname: Chen
– volume: 15
  start-page: 4448
  year: 2013
  ident: C9CE00377K-(cit13)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c3ce26986h
  contributor:
    fullname: Nanubolu
– volume: 13
  start-page: 3546
  year: 2013
  ident: C9CE00377K-(cit25)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg400518w
  contributor:
    fullname: Geng
– volume: 11
  start-page: 1823
  year: 2009
  ident: C9CE00377K-(cit4)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/B904616J
  contributor:
    fullname: Aitipamula
SSID ssj0014110
Score 2.3870637
Snippet A drug-drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization...
A drug–drug salt was prepared consisting of metformin and aspirin with two crystalline phases characterized. A hydrophilic surface induced recrystallization...
SourceID proquest
crossref
rsc
SourceType Aggregation Database
Publisher
StartPage 377
SubjectTerms Aspirin
Crystallography
Metformin
Recrystallization
Side effects
Title Characterization of drug-drug salt forms of metformin and aspirin with improved physicochemical properties
URI https://www.proquest.com/docview/2245603725
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLe67gIHxNdE2UCW4IY8Utv5Ok5VUfk8daJwiRzbqSKmZEoTpO3ElTP_IX8Jz7GTlK6HwcVNHDlS_X55z34fPyP0Eox0pEXqEz_MfMJVIEk0lZxIyUOfprFHhXHof_wULM75u5W_Go1-bmUtNXV6Kq_31pX8j1ShD-RqqmT_QbL9S6EDrkG-0IKEob2VjGc92_J1v_JTVbPuMhiYuXm1ERd1W6S4scH02lznNglZmEB7bku5TcVkVX6HFah1d5iztCyZwKXx2Fd1l2_YERtUV5t6XqxNjcngfy6bNm1PF2SVN1tu6dYluyiLNfms8yGpwGq9RSMKYpobfuyvIidfSmdenXfCaT-rSnlgqI4tzcWp3tPn9K-tkHY4o_6WNmWhPVTEWWa4ZXu1vscMaeosns0NnU74frBtXTx_x-T1iYhtCJ7FyTD2AB1S0Fn-GB2ezZdvP_QhKT611BbdX-i4bln8ehj99-pm2LIcVN15Mu26ZXkf3XMbDnxm0fMAjXTxEN3doqF8hC52cYTLDBvo_P7xy_xggyDcIsg86RGEAUHYIQgbBOEOQXgHQXhA0GN0_ma-nC2IO4WDSND3NWGSwiZABCpQWgSxCIQSgsJnHGg1lVOWhtSTYaSVllyrLOUslD7sglWQUeplmh2hcVEW-gnCngwiJthUepJzRcFWhJmnw0wxn3EvUhP0opu95NKSrSQ3JTRBJ93EJu5j3CTUBPDhMfUn6Agmux8vY6nbcd-e3urtx-iOwbH1sp2gcV01-hmsO-v0uUPEHwp5hsg
link.rule.ids 315,783,787,4031,27935,27936,27937
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+drug%E2%80%93drug+salt+forms+of+metformin+and+aspirin+with+improved+physicochemical+properties&rft.jtitle=CrystEngComm&rft.au=Zhou%2C+Wen-Xiu&rft.au=Zhao%2C+Hong-Wei&rft.au=Chen%2C+Huan-Huan&rft.au=Zhang%2C+Zai-Yong&rft.date=2019&rft.issn=1466-8033&rft.eissn=1466-8033&rft.volume=21&rft.issue=25&rft.spage=3770&rft.epage=3773&rft_id=info:doi/10.1039%2FC9CE00377K&rft.externalDBID=n%2Fa&rft.externalDocID=10_1039_C9CE00377K
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-8033&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-8033&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-8033&client=summon